Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
Open Access
- 15 December 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 754524
Abstract
Poly (ADP-ribose) polymerase (PARP) inhibitors constitute an important treatment option for ovarian cancer nowadays. The magnitude of benefit from PARP inhibitors is influenced by the homologous recombination status, with greater benefit observed in patients with BRCA mutated or BRCA wild-type homologous recombination deficient (HRD) tumors. Although some PARP inhibitor activity has been shown in homologous recombination proficient (HRP) ovarian tumors, its clinical relevance as a single agent is unsatisfactory in this population. Furthermore, even HRD tumors present primary or secondary resistance to PARP inhibitors. Strategies to overcome treatment resistance, as well as to enhance PARP inhibitors’ efficacy in HRP tumors, are highly warranted. Diverse combinations are being studied with this aim, including combinations with antiangiogenics, immunotherapy, and other targeted therapies. This review discusses the rationale for developing therapy combinations with PARP inhibitors, the current knowledge, and the future perspectives on this issue.Keywords
This publication has 86 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionCancer Discovery, 2012
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast CancerCancer Discovery, 2012
- PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and ChemotherapyClinical Cancer Research, 2012
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasCancer Research, 2011
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNature Medicine, 2011
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cellsProceedings of the National Academy of Sciences, 2011
- MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint ArrestGenes & Cancer, 2010
- Negative Regulation of AKT Activation by BRCA1Cancer Research, 2008
- Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repairNature Genetics, 2007